Malignes Melanom

Diagnostik:

RB-T002: Identifikation von individuellen Krebsmutationen und Testung ihrer Immunogenität

  • Status: offen 

Decide II: Decision for or against Anti-PD-1 Treatment In Adjuvant Setting of Patients across Europe with Resected Stage IIB/IIC Melanoma

  • Status: Rekrutierung offen

 

Stadium I:

Jimmy Mel: A randomized, double-blind, parallel-group study to compare pharmacokinetics of GME751 (proposed pembrolizumab biosimilar) and US-licensed and EUauthorized Keytruda® in participants with stage II and III melanoma requiring adjuvant treatment with pembrolizumab

Stadium II:

Derzeit keine Studien

 

Stadium III:

BNT111-01: Open-label, randomized Phase II trial with BNT111 and cemiplimab in combination or as single agents in patients with anti-PD-1-refractory/relapsed, unresectable Stage III or IV melanoma

R3767-ONC-2011 Harmony: A Phase 3 Trial of Fianlimab (REGN3767, anti-LAG-3) + Cemiplimab versus Pembrolizumab in Patients with Previously Untreated Unresectable locally Advanced or Metastatic Melanoma

Stadium IV:

 

BNT111-01: Open-label, randomized Phase II trial with BNT111 and cemiplimab in combination or as single agents in patients with anti-PD-1-refractory/relapsed, unresectable Stage III or IV
melanoma

DICIT: Efficacy of diclofenac added to an approved, ongoing PD-1 inhibitor therapy that achieved stable disease as best response in metastatic melanoma patients. A single arm phase II trial

  • Status: Rekrutierung offen

Huyabio HBI-8000-303: Phase 3 Study of HBI-8000 Combined with Nivolumab vs. Placebo with Nivolumab in Patients with Unresectable or Metastatic Melanoma Not Previously Treated with PD-1 or PD-L1 Inhibitors – HDAC-Inhibitor in Kombination mit Anti-PD1-Blockade 

  • Status: Rekrutierung abgeschlossen

MONETTE: Phase 2 Study of Ceralasertib Monotherapy and Ceralasertib plus Durvalumab in Patients with Unresectable or Advanced Melanoma and Primary or Secondary Resistance to PD-(L)1 – Inhibition der Serine/Threonine Proteinkinase in Kombination mit Anti-PD1-Blockade - auch vorbehandelte Patienten

  • Status: Rekrutierung abgeschlossen

IO102-103: Phase 3 trial of IO102-IO103 dual-antigen immunotherapeutic plus pembrolizumab versus pembrolizumab alone in unresectable or metastatic (advanced) melanoma- Kombinierter IDO-PD-L1-mAB

  • Status: Rekrutierung abgeschlossen